Vaccine CDMO Market Size to Hit USD 11.16 Billion by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Vaccine CDMO Market

5.1. COVID-19 Landscape: Vaccine CDMO Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Vaccine CDMO Market, By Modality

8.1. Vaccine CDMO Market, by Modality

8.1.1. mRNA vaccines

8.1.1.1. Market Revenue and Forecast

8.1.2. Viral-vector vaccines

8.1.2.1. Market Revenue and Forecast

8.1.3. Recombinant protein vaccines

8.1.3.1. Market Revenue and Forecast

8.1.4. Inactivated/subunit vaccines

8.1.4.1. Market Revenue and Forecast

Chapter 9. Global Vaccine CDMO Market, By Expression System / Platform

9.1. Vaccine CDMO Market, by Expression System / Platform

9.1.1. Mammalian cell culture (e.g., CHO, Vero)

9.1.1.1. Market Revenue and Forecast

9.1.2. Bacterial/E. coli

9.1.2.1. Market Revenue and Forecast

9.1.3. Yeast cells

9.1.3.1. Market Revenue and Forecast

9.1.4. Insect cells (baculovirus)

9.1.4.1. Market Revenue and Forecast

Chapter 10. Global Vaccine CDMO Market, By Manufacturing Scale

10.1. Vaccine CDMO Market, by Manufacturing Scale

10.1.1. Clinical scale (Phase I/II)

10.1.1.1. Market Revenue and Forecast

10.1.2. Commercial scale

10.1.2.1. Market Revenue and Forecast

10.1.3. Emergency / surge-capacity (pandemic response)

10.1.3.1. Market Revenue and Forecast

Chapter 11. Global Vaccine CDMO Market, By Dosage Form / Presentation

11.1. Vaccine CDMO Market, by Dosage Form / Presentation

11.1.1. Liquid formulation (vials/syringes)

11.1.1.1. Market Revenue and Forecast

11.1.2. Lyophilized (dry) presentation

11.1.2.1. Market Revenue and Forecast

11.1.3. Multi-dose presentations

11.1.3.1. Market Revenue and Forecast

11.1.4. Novel delivery forms (e.g., nasal sprays, patches)

11.1.4.1. Market Revenue and Forecast

Chapter 12. Global Vaccine CDMO Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Modality

12.1.2. Market Revenue and Forecast, by Expression System / Platform

12.1.3. Market Revenue and Forecast, by Manufacturing Scale

12.1.4. Market Revenue and Forecast, by Dosage Form / Presentation

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Modality

12.1.5.2. Market Revenue and Forecast, by Expression System / Platform

12.1.5.3. Market Revenue and Forecast, by Manufacturing Scale

12.1.5.4. Market Revenue and Forecast, by Dosage Form / Presentation

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Modality

12.1.6.2. Market Revenue and Forecast, by Expression System / Platform

12.1.6.3. Market Revenue and Forecast, by Manufacturing Scale

12.1.6.4. Market Revenue and Forecast, by Dosage Form / Presentation

12.2. Europe

12.2.1. Market Revenue and Forecast, by Modality

12.2.2. Market Revenue and Forecast, by Expression System / Platform

12.2.3. Market Revenue and Forecast, by Manufacturing Scale

12.2.4. Market Revenue and Forecast, by Dosage Form / Presentation

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Modality

12.2.5.2. Market Revenue and Forecast, by Expression System / Platform

12.2.5.3. Market Revenue and Forecast, by Manufacturing Scale

12.2.5.4. Market Revenue and Forecast, by Dosage Form / Presentation

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Modality

12.2.6.2. Market Revenue and Forecast, by Expression System / Platform

12.2.6.3. Market Revenue and Forecast, by Manufacturing Scale

12.2.6.4. Market Revenue and Forecast, by Dosage Form / Presentation

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Modality

12.2.7.2. Market Revenue and Forecast, by Expression System / Platform

12.2.7.3. Market Revenue and Forecast, by Manufacturing Scale

12.2.7.4. Market Revenue and Forecast, by Dosage Form / Presentation

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Modality

12.2.8.2. Market Revenue and Forecast, by Expression System / Platform

12.2.8.3. Market Revenue and Forecast, by Manufacturing Scale

12.2.8.4. Market Revenue and Forecast, by Dosage Form / Presentation

12.3. APAC

12.3.1. Market Revenue and Forecast, by Modality

12.3.2. Market Revenue and Forecast, by Expression System / Platform

12.3.3. Market Revenue and Forecast, by Manufacturing Scale

12.3.4. Market Revenue and Forecast, by Dosage Form / Presentation

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Modality

12.3.5.2. Market Revenue and Forecast, by Expression System / Platform

12.3.5.3. Market Revenue and Forecast, by Manufacturing Scale

12.3.5.4. Market Revenue and Forecast, by Dosage Form / Presentation

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Modality

12.3.6.2. Market Revenue and Forecast, by Expression System / Platform

12.3.6.3. Market Revenue and Forecast, by Manufacturing Scale

12.3.6.4. Market Revenue and Forecast, by Dosage Form / Presentation

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Modality

12.3.7.2. Market Revenue and Forecast, by Expression System / Platform

12.3.7.3. Market Revenue and Forecast, by Manufacturing Scale

12.3.7.4. Market Revenue and Forecast, by Dosage Form / Presentation

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Modality

12.3.8.2. Market Revenue and Forecast, by Expression System / Platform

12.3.8.3. Market Revenue and Forecast, by Manufacturing Scale

12.3.8.4. Market Revenue and Forecast, by Dosage Form / Presentation

12.4. MEA

12.4.1. Market Revenue and Forecast, by Modality

12.4.2. Market Revenue and Forecast, by Expression System / Platform

12.4.3. Market Revenue and Forecast, by Manufacturing Scale

12.4.4. Market Revenue and Forecast, by Dosage Form / Presentation

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Modality

12.4.5.2. Market Revenue and Forecast, by Expression System / Platform

12.4.5.3. Market Revenue and Forecast, by Manufacturing Scale

12.4.5.4. Market Revenue and Forecast, by Dosage Form / Presentation

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Modality

12.4.6.2. Market Revenue and Forecast, by Expression System / Platform

12.4.6.3. Market Revenue and Forecast, by Manufacturing Scale

12.4.6.4. Market Revenue and Forecast, by Dosage Form / Presentation

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Modality

12.4.7.2. Market Revenue and Forecast, by Expression System / Platform

12.4.7.3. Market Revenue and Forecast, by Manufacturing Scale

12.4.7.4. Market Revenue and Forecast, by Dosage Form / Presentation

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Modality

12.4.8.2. Market Revenue and Forecast, by Expression System / Platform

12.4.8.3. Market Revenue and Forecast, by Manufacturing Scale

12.4.8.4. Market Revenue and Forecast, by Dosage Form / Presentation

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Modality

12.5.2. Market Revenue and Forecast, by Expression System / Platform

12.5.3. Market Revenue and Forecast, by Manufacturing Scale

12.5.4. Market Revenue and Forecast, by Dosage Form / Presentation

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Modality

12.5.5.2. Market Revenue and Forecast, by Expression System / Platform

12.5.5.3. Market Revenue and Forecast, by Manufacturing Scale

12.5.5.4. Market Revenue and Forecast, by Dosage Form / Presentation

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Modality

12.5.6.2. Market Revenue and Forecast, by Expression System / Platform

12.5.6.3. Market Revenue and Forecast, by Manufacturing Scale

12.5.6.4. Market Revenue and Forecast, by Dosage Form / Presentation

Chapter 13. Company Profiles

13.1. Lonza

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Catalent

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Thermo Fisher Scientific

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Siegfried (formerly Swiss fill & finish or Siegfried Switzerland)

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Wacker Biotech

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Alcami

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Virchow Biotech

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. BioNTech Manufacturing

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Emergent BioSolutions

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Alcami

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms Vaccine CDMO

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The vaccine CDMO market size is expected to increase from USD 4.67 billion in 2024 to USD 11.16 billion by 2034.

The vaccine CDMO market is expected to grow at a compound annual growth rate (CAGR) of around 9.10% from 2025 to 2034.

The major players in the vaccine CDMO market include Lonza, Catalent, Thermo Fisher Scientific, Siegfried (formerly Swiss fill & finish or Siegfried Switzerland), Wacker Biotech, Alcami, Virchow Biotech, BioNTech Manufacturing, Emergent BioSolutions, Alcami, Novasep, Samsung Biologics, Boehringer Ingelheim BioXcellence, Fujifilm Diosynth Biotechnologies, Recipharm, Almac Group, Vetter Pharma, Thermogenesis, AGC Biologics, and Richter-Helm BioLogics.

The driving factors of the vaccine CDMO market are the raised funding from both the public as well as private sectors seeks to encourage innovations in vaccine design along with production processes.

North America region will lead the global vaccine CDMO market during the forecast period 2025 to 2034.